Continue to learn
On the afternoon of August 12, 2022, an eight-person expert team led by Party Secretary Mr. Jun Yuan and Deputy Director Ms. Lei Yang of the Sichuan Institute for Drug Control visited MAXVAX. Among those were experts from the Institute for Inspection of Biological Products and the Biological Sample Testing Center. Maxvax’s General Manager Dr. Dexiang Chen, quality control team, R&D team, operation management, and key technicians gave the visiting team a warm welcome. The two sides had a meeting, after which the expert team visited our laboratory and pilot workshop.
more >On the afternoon of May 19, 2022, a four-man expert panel from the Sichuan Provincial Laboratory Animal Management Committee visited Maxvax Biotech and conducted the on-site acceptance of an animal laboratory on the 5th floor of its R&D Center in Chengdu.
more >Recently, Chengdu Maxvax Biotechnology ("Maxvax Biotech") announced that it has raised nearly RMB 500 million (approx. $74 million) from a Series B funding led by China Life Equity Investment and participated by the original shareholders Sherpa Healthcare Partners and GL Ventures, with follow-up investments from two new investors, Shizhen Capital and Xinshang Capital. The fund will mainly be used for the clinical trials of the company’s multiple vaccine pipelines, the construction of its Shanghai production base, and the expansion and improvement of its talent team.
more >1st launch in China, new technology route | MaxHealth's recombinant rotavirus subunit vaccine program enters clinical trials stage
more >Maxvax Biotech held a grand commencement ceremony for the "Innovative Vaccine Production Platform Project" of Shanghai Maxvax Biotech, a wholly-owned subsidiary of Chengdu Maxvax Biotech, in the Lingang New Area of Shanghai on June 27, 2022. Leaders of Shanghai Lingang Fengxian Economic Development Company (Chairman Mr. Linkun Zou, Assistant General Manager Ms. Aiying Ding, and Deputy Director of Project Promotion Department Mr. Jie Duan) and leaders of Maxvax (Deputy General Manager Mr. Yi Jin and Mr. Yichun Dong), and other leaders and partners attended the event.
more >On March 13, 2020, Maxvax was awarded the “Certificate of Innovation Platform Technology” to develop adjuvants for use in COVID-19 vaccines. The award was given by the Chengdu Hi-tech Zone under its policy of supporting “enterprises to develop major innovation platform projects” for the prevention and control of the COVID-19 pandemic.
more >
On the afternoon of August 12, 2022, an eight-person expert team led by Party Secretary Mr. Jun Yuan and Deputy Director Ms. Lei Yang of the Sichuan Institute for Drug Control visited MAXVAX. Among those were experts from the Institute for Inspection of Biological Products and the Biological Sample Testing Center. Maxvax’s General Manager Dr. Dexiang Chen, quality control team, R&D team, operation management, and key technicians gave the visiting team a warm welcome. The two sides had a meeting, after which the expert team visited our laboratory and pilot workshop.
more >
Recently, Chengdu Maxvax Biotechnology ("Maxvax Biotech") announced that it has raised nearly RMB 500 million (approx. $74 million) from a Series B funding led by China Life Equity Investment and participated by the original shareholders Sherpa Healthcare Partners and GL Ventures, with follow-up investments from two new investors, Shizhen Capital and Xinshang Capital. The fund will mainly be used for the clinical trials of the company’s multiple vaccine pipelines, the construction of its Shanghai production base, and the expansion and improvement of its talent team.
more >
Maxvax Biotech held a grand commencement ceremony for the "Innovative Vaccine Production Platform Project" of Shanghai Maxvax Biotech, a wholly-owned subsidiary of Chengdu Maxvax Biotech, in the Lingang New Area of Shanghai on June 27, 2022. Leaders of Shanghai Lingang Fengxian Economic Development Company (Chairman Mr. Linkun Zou, Assistant General Manager Ms. Aiying Ding, and Deputy Director of Project Promotion Department Mr. Jie Duan) and leaders of Maxvax (Deputy General Manager Mr. Yi Jin and Mr. Yichun Dong), and other leaders and partners attended the event.
more >
On the afternoon of May 19, 2022, a four-man expert panel from the Sichuan Provincial Laboratory Animal Management Committee visited Maxvax Biotech and conducted the on-site acceptance of an animal laboratory on the 5th floor of its R&D Center in Chengdu.
more >
1st launch in China, new technology route | MaxHealth's recombinant rotavirus subunit vaccine program enters clinical trials stage
more >
On March 13, 2020, Maxvax was awarded the “Certificate of Innovation Platform Technology” to develop adjuvants for use in COVID-19 vaccines. The award was given by the Chengdu Hi-tech Zone under its policy of supporting “enterprises to develop major innovation platform projects” for the prevention and control of the COVID-19 pandemic.
more >